Head & Neck Cancer

This study is the first of its kind to report modest, promising clinical activity with tipifarnib in this patient population.

The FDA approved an expanded indication for the HPV 9-valent vaccine, recombinant for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.

A review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.

Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma.

Treating head and neck cancer with selective neck dissection showed an improvement in shoulder function when level 2b neck dissection was omitted in treatment, according to a recent study.

Patients with head and neck cancer saw better overall survival when treated at academic comprehensive cancer programs and integrated network cancer programs, compared to comprehensive community cancer programs and community cancer programs.

This research indicated that routine HPV testing may be necessary for patients with squamous cell carcinoma.

Administering a high dose of gabapentin also increased the percentage of patients who required no opioid during treatment, indicating that patients were possibly gleaning benefits from gabapentin in both treatment arms.

These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.

The drug candidate tipifarnib (Zarnestra) is being clinically studied for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma after progression on platinum therapy. 

True acupuncture resulted in fewer and less severe radiation-induced xerostomia symptoms in this phase III study.

Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.

Researchers found that there is an increasing incidence of late stage head and neck cancer in the U.S., highlighting the need for continuous public health efforts toward early detection.

A new possible surveillance model suggests scanning patients with head and neck cancer treated with radiotherapy less frequently could be more cost-effective and time-effective.

Machine learning of ultrasound scans could provide a preliminary method of screening for thyroid cancer.

A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Data from a new study show the importance of taking preventative measures against contracting human papillomavirus, including urging patients to get the HPV vaccine.

Researchers compared the swallowing-related quality-of-life scores of patients with oropharyngeal squamous cell carcinoma who received radiotherapy and patients who received transoral robotic surgery with neck dissection.

A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.

Researchers surveyed patients who underwent surgery for thyroid cancer and found a high number reported voice abnormalities post-operation.

Potential new developments have been made in detecting sentinel lymph nodes for patients with localized oral cancers.

The FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

The phase III KEYNOTE-048 study compared pembrolizumab plus chemotherapy vs the EXTREME regimen in patients with recurrent/metastatic head and neck cancer.

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.

Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.